



**UNICHEM
LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198
Tel. No. : 91 (22) 66888333
Website : <http://www.unichemlabs.com>
CIN : L99999MH1962PLC012451.

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

29.1.2016

Department of Corporate Services
Bombay Stock Exchange Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai - 400 001

Mr. Hari K.
Asst .Vice President- Operations
National Stock Exchange of India Ltd
Exchange Plaza, Bandra - Kurla Complex
Bandra (East), Mumbai - 400 051

Ref: BSE Scrip Code: 506690 : NSE Symbol - UNICHEMLAB

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith the press release pertaining to receipt of ANDA approval from United States Food and Drug administration for Alfuzosin Hydrochloride Extended-Release Tablets USP 10 mg.

Please take the above on record.

For UNICHEM LABORATORIES LIMITED

Neema Thakore
Head - Legal & Company Secretary



UNICHEM
LABORATORIES LTD.

UNICHEM LABORATORIES LIMITED

Unichem Bhavan
Prabhat Estate, Off S.V.Road,
Jogeshwari (West),
Mumbai - 400 102.
Tel. No: +91 (22) 66 888 333
Fax. No: +91 (22) 267 843 91/ 5198
CIN: L99999MH1962PLC012451

Press Release

Mumbai, Friday January 29, 2016

Unichem Laboratories receives Final ANDA approval from USFDA for Alfuzosin Hydrochloride Extended-Release Tablets USP

Unichem Laboratories Limited is pleased to announce that it has received Final ANDA approval (Tentative Approval was received earlier) from the United States Food and Drug Administration (USFDA) for Alfuzosin Hydrochloride Extended-Release Tablets USP.

Alfuzosin Hydrochloride Extended-Release Tablets USP 10mg is therapeutically equivalent to Uroxatral Extended-release Tablets, 10 mg, of *Concordia Pharmaceuticals, Inc. (Concordia)*.

Alfuzosin Hydrochloride Extended-Release Tablets USP is the Company's first PARA IV ANDA approval from the USFDA.

Alfuzosin HCl is an alpha adrenergic antagonist, indicated for the treatment of signs and symptoms of benign prostatic hyperplasia in adults.

The product will be commercialized from Unichem's Goa plant. Active Pharmaceutical Ingredient will also be made in house at Pithampur API Plant.

Unichem Laboratories Limited now has total of 20 ANDA approvals from USFDA.



UNICHEM
LABORATORIES LTD.

About Unichem Laboratories Limited

Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India and several other markets across the world. In India, the company is a leader in niche therapy areas of cardiology, neurology, orthopedics and anti-infectives. The company has strong skills in product development, process chemistry and manufacturing of complex API as well as dosage forms. More information about the company can be found at www.unichemlabs.com

For more information please contact:

Ms. Neema Thakore

Ph: +91-22-66888 404

E-mail: neema.thakore@unichemlabs.com

Mr. Rakesh Parikh/ Mr. Monish Shah

Ph: +91-22-66888 414

Ph: +91-22-66888 509

E-mail: rparikh@unichemlabs.com

monish.shah@unichemlabs.com

Disclaimer: This press release includes forward-looking statements. We have based these forward-looking statements on our current expectations and projections about future events. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially. Such factors include, but are not limited to, changes in local and global economic conditions, our ability to successfully implement our strategy, the market acceptance of and demand for our products, our growth and expansion, technological change and our exposure to market risks. By their nature, these expectations and projections are only estimates and could be materially different from actual results in the future.